Bisphosphonates and atherosclerosis

General Pharmacology: Vascular System

Volumn 35, Issue 6, 2000, Pages 287-296

  Ylitalo, Ritva ^a,b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Artery; Atherosclerosis; Bisphosphonates; Calcium; Cardiovascular disease; Macrophages

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PAMIDRONIC ACID; SR 9223 I; TETRAISOPROPYL 2 (3,5 DI TERT BUTYL 4 HYDROXYPHENYL)ETHYL 1,1 DIPHOSPHONATE; UNCLASSIFIED DRUG; CHOLESTEROL;

AORTA ATHEROSCLEROSIS; ARTERY CALCIFICATION; ARTERY WALL; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CALORIC INTAKE; CAROTID ARTERY; CHOLESTEROL SYNTHESIS; DOSE RESPONSE; DRUG ACCUMULATION; DRUG CAPSULE; DRUG EFFECT; DRUG MECHANISM; ENCAPSULATION; ENZYME INHIBITION; FIBROMUSCULAR DYSPLASIA; FOAM CELL; HUMAN; LIPID STORAGE; MACROPHAGE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TISSUE LEVEL; ANIMAL; ARTERIOSCLEROSIS; BLOOD VESSEL; CALCINOSIS; METABOLISM; PATHOLOGY;

ANIMALS; ARTERIOSCLEROSIS; BLOOD VESSELS; CALCINOSIS; CHOLESTEROL; DIPHOSPHONATES; HUMANS; MACROPHAGES;

EID: 1842853752     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(01)00121-5     Document Type: Review

References (83)

1. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis
2. 1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase
3. Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry
4. Diphosphonates in the treatment of myositis ossificans
5. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase
6. Bone morphogenic protein expression in human atherosclerotic lesions
7. Regulatory mechanisms in vascular calcification
8. The effect of polyphloretin phosphate, polyestradiol phosphate, a diphosphonate and a polyphosphate on calcification induced by dihydrotachysterol in skin, aorta and kidney of rats
9. Diphosphonate treatment of calcinosis universalis
10. The effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) on necrosis of atherosclerotic lesions
11. Apoptosis in phagocytotic cells of lymphoid tissue in rainbow trout (Oncorhynchus mykiss) following administration of clodronate liposomes
12. The effects of diphosphonates on the growth and glycolysis of connective-tissue cells in culture
13. The subcellular distribution of [14]dichloromethylenebisphosphonate and [14]1-hydroxyethylidene-1,1-bisphosphonate in cultured calvaria cells
14. Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease
15. Bisphosphonates. Pharmacology and use in the treatment of tumor-induced hypercalcaemic and metastatic bone diseases
16. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo
17. The inhibitory effect of phosphonates of the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo
18. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo
19. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(β, γ-dichloromethylene) triphosphate, by mammalian cells in vitro
20. Identification of the molecular mechanism of action of clodronate
21. Studies of the oral bioavailability of alendronate
22. Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound
23. Unified concept on the role of acid mucopolysaccharides and connective tissue proteins in the accumulation of lipids, lipoproteins, and calcium in the atherosclerotic plaque
24. Influence of the anticalcifying agent, ethane-1-hydroxy-1,1-diphosphonate (EHDP) on pre-established atheroma in rabbits
25. 2MDP) on the development of atherosclerosis in the cynomolgus monkey
26. Effects of anticalcifying and antifibrotic drugs on pre-established atherosclerosis in the rabbit
27. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
28. Multiple extra-bone accumulations of technetium-99m-HMDP
29. Hypocholesterolaemic and antiatherosclerotic effects of tetra-iso-propyl 2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethyl-1,1-diphosphonate (SR-9223i)
30. Alendronate. A review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis
31. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis
32. Decrease in carotid intima-media thickness after 1-year therapy with etidronate for osteopenia associated with type 2 diabetes
33. The effect of agent interfering with soft tissue calcification and cell proliferation on calcific fibrous-fatty plaques in rabbits
34. Atherosclerosis: Prevention by agents not affecting abnormal levels of blood lipids
35. The visualization of femoral vessels in delayed bone scans - A sign of atherosclerosis? A comparison of 99mTc-MDP and 99mTc-DPD
36. Lack of effect of phenformin, pyridinolcarbamate combined with a anticalcifying agent, and an onion-garlic mixture on growth and necrosis of aortic atherosclerosis in ballooned swine
37. Physiological disposition of alendronate, a potent and anti-osteolytic bisphosphonate, in laboratory animals
38. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras
39. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein
40. Idiopathic infantile arterial calcification in siblings: Radiologic diagnosis and successful treatment
41. 14C-clodronate in mice and rats
42. The uptake of clodronate (dichloromethylene bisphosphonate) by macrophages in vivo and in vitro
43. Comparison of the distribution of three bisphosphonates in mice
44. Growth inhibition of macrophage-like and other cell types by liposome-encapsulated, calcium-bound and free bisphosphonates in vitro
45. Extensive arterial calcification of unknown etiology in a 29-year-old male
46. Pathogenesis of atherosclerosis
47. Osteopontin is expressed in human aortic valvular lesions
48. Lipid oxidation productions have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients
49. Clodronate inhibits contraction and prevents the action of L-type calcium channel antagonists in vascular smooth muscle
50. Macrophage-like RAW 264 cell line and time-resolved fluoroimmunoassay (TRFIA) as tools in screening drug effects on cytokine secretion
51. Pharmacokinetics of clodronate in patients with metastatic breast cancer
52. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption
53. Is overamplification of the normal macrophage defensive role critical to lesion development?
54. Intestinal absorption of disodium ethane-1-hydroxy-1,1-diphosphonate (disodium etidronate) using a deconvolution technique
55. Biophosphonates: Mechanism of action
56. Metabolism of halogenated bisphosphonates by the cellular slime mould Dictyostelium discoideum
57. Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum
58. Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide independent mechanism
59. Inhibition of growth of Dictyostelium discoideum amoebae by bisphosphonate drugs is dependent on cellular uptake
60. The effect of disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP) on a rabbit model of athero-arteriosclerosis
61. Lipid composition of aorta of Watanabe heritable hyperlipemic and comparably hypercholesterolemic fat-fed rabbits
62. The pathogenesis of atherosclerosis - A perspective for the 1990s
63. Treatment of myositis ossificans progressive with a diphosphonate
64. Human pharmacokinetics of tiludronate
65. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure
66. Vascular calcification - A passive process in need of inhibitors
67. Characteristic of clodronate-induced apoptosis in osteoclasts and macrophages
68. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity
69. Cytotoxic and migration inhibitory effects of bisphosphonates on macrophages
70. Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway
71. Suppression of viability and acetyl-LDL metabolism of RAW 264 macrophage-like and smooth muscle cells by bisphosphonates
72. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates
73. Animal models of atherosclerosis, their contributions and pitfalls
74. Calcification of vascular smooth muscle cell cultures: Inhibition by osteopontin
75. Contrasting effects of ethane-1-hydroxy-1,1-diphosphonate (EHDP) on the regression of two types of dietary-induced atherosclerosis
76. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man
77. Effects of clodronate (dichloro-methylene bisphosphonate) on the development of experimental atherosclerosis in rabbits
78. Accumulation of bisphosphonates in the aorta and some other tissues of healthy and atherosclerotic rabbits
79. Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro
80. Effects of liposome-encapsulated bisphosphonates on the acetylated LDL metabolism, lipid accumulation and viability of phagocyting cells
81. Suppression of immunoreactive macrophages in atheromatous lesions of rabbits by clodronate
82. Effects of etidronate and lovastatin on the regression of atherosclerosis in cholesterol-fed rabbits